

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2010; month=3; day=26; hr=14; min=33; sec=22; ms=714; ]

=====

Application No: 10587987

Version No: 2.0

**Input Set:****Output Set:****Started:** 2010-03-16 19:17:08.382**Finished:** 2010-03-16 19:17:16.576**Elapsed:** 0 hr(s) 0 min(s) 8 sec(s) 194 ms**Total Warnings:** 56**Total Errors:** 82**No. of SeqIDs Defined:** 56**Actual SeqID Count:** 56

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

**Input Set:**

**Output Set:**

**Started:** 2010-03-16 19:17:08.382  
**Finished:** 2010-03-16 19:17:16.576  
**Elapsed:** 0 hr(s) 0 min(s) 8 sec(s) 194 ms  
**Total Warnings:** 56  
**Total Errors:** 82  
**No. of SeqIDs Defined:** 56  
**Actual SeqID Count:** 56

Error code	Error Description
	This error has occurred more than 20 times, will not be displayed
E 341	'Xaa' position not defined SEQID (26) POS (6)
E 341	'Xaa' position not defined SEQID (26) POS (7)
E 341	'Xaa' position not defined SEQID (26) POS (8)
E 341	'Xaa' position not defined SEQID (27) POS (9)
E 341	'Xaa' position not defined SEQID (27) POS (10)
E 341	'Xaa' position not defined SEQID (30) POS (2)
E 341	'Xaa' position not defined SEQID (30) POS (3)
E 341	'Xaa' position not defined SEQID (30) POS (4)
E 341	'Xaa' position not defined SEQID (31) POS (2)
E 341	'Xaa' position not defined SEQID (31) POS (3)
E 341	'Xaa' position not defined SEQID (31) POS (4)
E 341	'Xaa' position not defined SEQID (32) POS (6)
E 341	'Xaa' position not defined SEQID (32) POS (7)
E 341	'Xaa' position not defined SEQID (32) POS (8)
E 341	'Xaa' position not defined SEQID (32) POS (9)
E 341	'Xaa' position not defined SEQID (32) POS (10)
E 341	'Xaa' position not defined SEQID (34) POS (2)
E 341	'Xaa' position not defined SEQID (34) POS (3)
E 341	'Xaa' position not defined SEQID (34) POS (4)
E 341	'Xaa' position not defined SEQID (35) POS (2)
	This error has occurred more than 20 times, will not be displayed



SEQUENCE LISTING

<110> Mixture Sciences, Inc.  
The Government of the United States of America, as Represented by the  
Secretary, Department of Health and Human Services  
Houghten, Richard A.  
Pinilla, Clemencia  
Martin, Roland  
Sturzebecher, Claus-Steffen  
Shukaliak-Quandt, Jaqueline  
McFarland, Henry F.

<120> PEPTIDE MIXTURES WITH IMMUNOMODULATORY  
ACTIVITY

<130> MCI.003NP

<140> 10587987

<141> 2010-03-16

<150> PCT/US2005/002962

<151> 2005-02-02

<150> 60/541,397

<151> 2004-02-02

<160> 56

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide

<220>

<221> VARIANT

<222> 1

<223> Xaa = F or W

<220>

<221> VARIANT

<222> 2

<223> Xaa = E or F

<220>

<221> VARIANT

<222> 3

<223> Xaa = E or K

<220>

<221> VARIANT  
<222> 4  
<223> Xaa = A, E or K

<220>  
<221> VARIANT  
<222> 5  
<223> Xaa = A, K or Y

<220>  
<221> VARIANT  
<222> (6) ... (7)  
<223> Xaa = A, N or Y

<220>  
<221> VARIANT  
<222> (8) ... (8)  
<223> Xaa = A, I, N or V

<220>  
<221> VARIANT  
<222> (9) ... (9)  
<223> Xaa = A, S or V

<400> 1  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr  
1 5 10

<210> 2  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide

<220>  
<221> VARIANT  
<222> 1  
<223> Xaa = E, F, W or Y

<220>  
<221> VARIANT  
<222> 2  
<223> Xaa = E, F, I, V, W or Y

<220>  
<221> VARIANT  
<222> 3  
<223> Xaa = E, F, K or Q

<220>

<221> VARIANT  
<222> 4  
<223> Xaa = A, E, K or Q

<220>  
<221> VARIANT  
<222> 5  
<223> Xaa = A, K, Q or Y

<220>  
<221> VARIANT  
<222> (6)...(6)  
<223> Xaa = A, N, Q or Y

<220>  
<221> VARIANT  
<222> (7)...(7)  
<223> Xaa = A, G, N, S or Y

<220>  
<221> VARIANT  
<222> (8)...(8)  
<223> Xaa = A, G, I, N, S or V

<220>  
<221> VARIANT  
<222> (9)...(9)  
<223> Xaa = A, I, Q, S or V

<220>  
<221> VARIANT  
<222> (10)...(10)  
<223> Xaa = I, K, R, S, V or Y

<400> 2  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 3  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide

<400> 3  
Glu Tyr Tyr Lys Glu Tyr Tyr Lys Glu Tyr Tyr Lys  
1 5 10

<210> 4  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide PLP 89-106

<400> 4  
Gly Phe Tyr Thr Thr Gly Ala Val Arg Gln Ile Phe Gly Asp Tyr Lys  
1 5 10 15  
Thr Thr

<210> 5  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide PLP 139-154

<400> 5  
His Cys Leu Gly Lys Trp Leu Gly His Pro Asp Lys Phe Val Gly Ile  
1 5 10 15

<210> 6  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide PLP 178-197

<400> 6  
Asn Thr Trp Thr Thr Cys Gln Ser Ile Ala Phe Pro Ser Lys Thr Ser  
1 5 10 15  
Ala Ser Ile Gly  
20

<210> 7  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide PLP 190-209

<400> 7  
Ser Lys Thr Ser Ala Ser Ile Gly Ser Leu Cys Ala Asp Ala Arg Met  
1 5 10 15  
Tyr Gly Val Leu  
20



<210> 8  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MBP 13-32

<400> 8  
Lys Tyr Leu Ala Thr Ala Ser Thr Met Asp His Ala Arg His Gly Phe  
1 5 10 15  
Leu Pro Arg His  
20

<210> 9  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MBP 83-99

<400> 9  
Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr  
1 5 10 15  
Pro

<210> 10  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MBP 111-129

<400> 10  
Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro Gly Phe Gly  
1 5 10 15  
Tyr Gly Gly

<210> 11  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MBP 131-155

<400> 11  
Ala Ser Asp Tyr Lys Ser Ala His Lys Gly Leu Lys Gly Val Asp Ala

1 5 10 15  
Gln Gly Thr Leu Ser Lys Ile Phe Lys  
20 25

<210> 12  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MBP 146-170

<400> 12  
Ala Gln Gly Thr Leu Ser Lys Ile Phe Lys Leu Gly Gly Arg Asp Ser  
1 5 10 15  
Arg Ser Gly Ser Pro  
20

<210> 13  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MOG 1-20

<400> 13  
Cys Gln Phe Arg Val Ile Gly Pro Arg His Pro Ile Arg Ala Leu Val  
1 5 10 15  
Gly Asp Glu Val  
20

<210> 14  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MOG 11-30

<400> 14  
Pro Ile Arg Ala Leu Val Gly Asp Glu Val Glu Leu Pro Cys Arg Ile  
1 5 10 15  
Ser Pro Gly Lys  
20

<210> 15  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MOG 21-40

<400> 15

Glu Leu Pro Cys Arg Ile Ser Pro Gly Lys Asn Ala Thr Gly Met Glu  
1 5 10 15  
Val Gly Trp Tyr  
20

<210> 16

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide MOG 35-55

<400> 16

Met Glu Val Gly Trp Tyr Arg Pro Pro Phe Ser Arg Val Val His Leu  
1 5 10 15  
Tyr Arg Asn Gly Lys  
20

<210> 17

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide CNPase 343-373

<400> 17

Glu Val Gly Glu Leu Ser Arg Gly Lys Leu Tyr Ser Leu Gly Asn Gly  
1 5 10 15  
Arg Trp Met Leu Thr Leu Ala Lys Asn Met Glu Val Arg Ala Ile  
20 25 30

<210> 18

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide CNPase 356-388

<400> 18

Gly Asn Gly Arg Trp Met Leu Thr Leu Ala Lys Asn Met Glu Val Arg  
1 5 10 15  
Ala Ile Phe Thr Gly Tyr Tyr Gly Lys Gly Lys Pro Val Pro Thr Gln  
20 25 30  
Gly

<210> 19

<211> 19

<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Artificially Synthesized Peptide MOBP 21-39  
  
<400> 19  
Phe Ser Ile His Cys Cys Pro Pro Phe Thr Phe Asn Asn Ser Lys Lys  
1 5 10 15  
Glu Ile Val

<210> 20  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide MOBP 31-49  
  
<400> 20  
Phe Leu Asn Ser Lys Lys Glu Ile Val Asp Arg Lys Tyr Ser Ile Cys  
1 5 10 15  
Lys Ser Gly

<210> 21  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide PLP 139-151

<400> 21  
His Ser Leu Gly Lys Trp Leu Gly His Pro Asp Lys Phe  
1 5 10

<210> 22  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY-10

<220>  
<221> VARIANT  
<222> (1)...(10)  
<223> Xaa = A, E, K or Y

<400> 22  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 23  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY-12

<220>  
<221> VARIANT  
<222> (1)...(12)  
<223> Xaa = A, E, K or Y

<400> 23  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 24  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY-15

<220>  
<221> VARIANT  
<222> (1)...(15)  
<223> Xaa = A, E, K or Y

<400> 24  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

<210> 25  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY-20

<220>  
<221> VARIANT  
<222> (1)...(20)  
<223> Xaa = A, E, K or Y

<400> 25  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15  
Xaa Xaa Xaa Xaa  
20

<210> 26  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY-10-DR2a

<220>  
<221> VARIANT  
<222> 1  
<223> Xaa = F, L, M or Y

<220>  
<221> VARIANT  
<222> 2-3, 5-8, 10  
<223> Xaa = A, E, K or Y

<220>  
<221> VARIANT  
<222> 4  
<223> Xaa = I, M, Q or V

<220>  
<221> VARIANT  
<222> 9  
<223> Xaa = K or R

<400> 26  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 27  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY-10-DR2b

<220>  
<221> VARIANT  
<222> 1  
<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 2-3, 5-6, 8-10  
<223> Xaa = A, E, K or Y

<220>  
<221> VARIANT  
<222> 4  
<223> Xaa = I, M, Q or V

<220>  
 <221> VARIANT  
 <222> 7  
 <223> Xaa = F, I, L, M or V

<400> 27  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5 10

<210> 28  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificially Synthesized Peptide GA TCC-1-10

<220>  
 <221> VARIANT  
 <222> 1  
 <223> Xaa = F or W

<220>  
 <221> VARIANT  
 <222> 2  
 <223> Xaa = E or F

<220>  
 <221> VARIANT  
 <222> 3  
 <223> Xaa = E or K

<220>  
 <221> VARIANT  
 <222> 4  
 <223> Xaa = A, E or K

<220>  
 <221> VARIANT  
 <222> 5  
 <223> Xaa = A, K or Y

<220>  
 <221> VARIANT  
 <222> (6) ... (7)  
 <223> Xaa = A, N or Y

<220>  
 <221> VARIANT  
 <222> (8) ... (8)  
 <223> Xaa = A, I, N or V

<220>  
 <221> VARIANT  
 <222> (9)...(9)  
 <223> Xaa = A, S or V

<400> 28  
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr  
 1 5 10

<210> 29  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificially Synthesized Peptide GA TCC-2-10

<220>  
 <221> VARIANT  
 <222> 1  
 <223> Xaa = E, F, W or Y

<220>  
 <221> VARIANT  
 <222> 2  
 <223> Xaa = E, F, I, V, W or Y

<220>  
 <221> VARIANT  
 <222> 3  
 <223> Xaa = E, F, K or Q

<220>  
 <221> VARIANT  
 <222> 4  
 <223> Xaa = A, E, K or Q

<220>  
 <221> VARIANT  
 <222> 5  
 <223> Xaa = A, K, Q or Y

<220>  
 <221> VARIANT  
 <222> (6)...(6)  
 <223> Xaa = A, N, Q or Y

<220>  
 <221> VARIANT  
 <222> (7)...(7)  
 <223> Xaa = A, G, N, S or Y



<220>  
<221> VARIANT  
<222> (8)...(8)  
<223> Xaa = A, G, I, N, S or V

<220>  
<221> VARIANT  
<222> (9)...(9)  
<223> Xaa = A, I, Q, S or V

<220>  
<221> VARIANT  
<222> (10)...(10)  
<223> Xaa = I, K, R, S, V or Y

<400> 29  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 30  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide 19a.a.-10-IAs

<220>  
<221> VARIANT  
<222> 1-4, 6, 9  
<223> Xaa = A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R,  
T, V, W or Y

<220>  
<221> VARIANT  
<222> 5  
<223> Xaa = K, H, R or V

<220>  
<221> VARIANT  
<222> 7  
<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 8  
<223> Xaa = H, R or K

<220>  
<221> VARIANT  
<222> 10  
<223> Xaa = P or I

<400> 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1 5 10

<210> 31

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY-10-IAs

<220>

<221> VARIANT

<222> 1-4, 6, 9

<223> Xaa = A, E, K or Y

<220>

<221> VARIANT

<222> 5

<223> Xaa = K, H, R or V

<220>

<221> VARIANT

<222> 7

<223> Xaa = I, L or V

<220>

<221> VARIANT

<222> 8

<223> Xaa = H, R or K

<220>

<221> VARIANT

<222> 10

<223> Xaa = P or I

<400> 31

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1 5 10

<210> 32

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY-10-IAs-mis

<220>

<221> VARIANT

<222> 1

<223> Xaa = P or I

<220>  
<221> VARIANT  
<222> 2  
<223> Xaa = H, R or K

<220>  
<221> VARIANT  
<222> 3  
<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 4  
<223> Xaa = K, H, R or V

<220>  
<221> VARIANT  
<222> 5-10  
<223> Xaa = A, E, K or Y

<400> 32  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 33  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide 19 a.a.-10

<220>  
<221> VARIANT  
<222> (1)...(10)  
<223> Xaa = A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R,  
T, V, W or Y

<400> 33  
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 34  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>  
<221> VARIANT  
<222> 1-4, 6, 9  
<223> Xaa = A, E, K or Y

<220>  
<221> VARIANT  
<222> 7  
<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 8  
<223> Xaa = H, R or K

<220>  
<221> VARIANT  
<222> 10  
<223> Xaa = P or I

<400> 34  
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 35  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>  
<221> VARIANT  
<222> 1-4, 6, 9  
<223> Xaa = A, E, K or Y

<220>  
<221> VARIANT  
<222> 7  
<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 8  
<223> Xaa = H, R or K

<220>  
<221> VARIANT  
<222> 10  
<223> Xaa = P or I

<400> 35  
Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 36  
<211> 10  
<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT

<222> 1-4, 6, 9

<223> Xaa = A, E, K or Y

<220>

<221> VARIANT

<222> 7

<223> Xaa = I, L or V

<220>

<221> VARIANT

<222> 8

<223> Xaa = H, R or K

<220>

<221> VARIANT

<222> 10

<223> Xaa = P or I

<400> 36

Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa

1 5 10

<210> 37

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT

<222> 1-4, 6, 9

<223> Xaa = A, E, K or Y

<220>

<221> VARIANT

<222> 7

<223> Xaa = I, L or V

<220>

<221> VARIANT

<222> 8

<223> Xaa = H, R or K

<220>

<221> VARIANT

<222> 10

<223> Xaa = P or I

<400> 37

Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Xaa

1 5 10

<210> 38

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT

<222> 1-4, 6, 9

<223> Xaa = A, E, K or Y

<220>

<221> VARIANT

<222> 7

<223> Xaa = I, L or V

<220>

<221> VARIANT

<222> 8

<223> Xaa = H, R or K

<220>

<221> VARIANT

<222> 10

<223> Xaa = P or I

<400> 38

Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa

1 5 10

<210> 39

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT

<222> 1-4, 6, 9

<223> Xaa = A, E, K or Y

<220>

<221> VARIANT

<222> 7

<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 8  
<223> Xaa = H, R or K

<220>  
<221> VARIANT  
<222> 10  
<223> Xaa = P or I

<400> 39  
Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 40  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>  
<221> VARIANT  
<222> 1-4, 6, 9  
<223> Xaa = A, E, K or Y

<220>  
<221> VARIANT  
<222> 7  
<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 8  
<223> Xaa = H, R or K

<220>  
<221> VARIANT  
<222> 10  
<223> Xaa = P or I

<400> 40  
Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa  
1 5 10

<210> 41  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT  
<222> 1-4, 6, 9  
<223> Xaa = A, E, K or Y

<220>  
<221> VARIANT  
<222> 7  
<223> Xaa = I, L or V

<220>  
<221> VARIANT  
<222> 8  
<223> Xaa = H, R or K

<220>  
<221> VARIANT  
<222> 10  
<223> Xaa = P or I

<400> 41  
Xaa Xaa Xaa Xaa Ile Xaa Xaa Xa